ArticleInternal medicine (Tokyo, Japan)2026
Safe Childbirth in a Patient with Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 30-year-old woman presented with optic neuritis. On an examination, aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (NMOSD) was diagnosed. Following immunotherapy for the NMOSD attack, prednisolone 20 mg was prescribed as maintenance therapy to prevent further relapse. Although the attacks recurred six times before and after her first delivery, none occurred after the addition of satralizumab. She became pregnant again at 41 years old and gave birth safely. No attacks occurred with prednisolone 10 mg and satralizumab. The concentration of satralizumab in the umbilical cord blood was approximately half that in the maternal serum, but the infant developed well with no malformations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.